Part VI: Summary of the risk management plan

Summary of risk management plan for Biquetan (Quetiapine)

This is a summary of the risk management plan (RMP) for Biquetan. The RMP details important risks of Biquetan, how these risks can be minimised, and how more information will be obtained about Biquetan's risks and uncertainties (missing information).

Biquetan's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Biquetan should be used.

Important new concerns or changes to the current ones will be included in updates of Biquetan's RMP.

I. The medicine and what it is used for

Biquetan is authorised for treatment of schizophrenia, bipolar disorder and add-on treatment of major depressive episodes in patients with Major Depressive Disorder (MDD) who have had sub-optimal response to antidepressant monotherapy (see SmPC for the full indication). It contains quetiapine as the active substance and it is given orally.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Biquetan, together with measures to minimise such risks and the proposed studies for learning more about Biquetan's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine’s packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine’s legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In the case of Biquetan, these measures are supplemented with *additional risk minimisation measures* mentioned under relevant important risks, below.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including PSUR assessment, so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

If important information that may affect the safe use of Biquetan is not yet available, it is listed under ‘missing information’ below.

II.A List of important risks and missing information

Important risks of Biquetan are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Biquetan. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

List of important risks and missing information	
Important identified risks	• Extrapyramidal symptoms • Somnolence • Weight gain • Lipid changes (increased cholesterol [including increased LDLs], increased triglycerides, and decreased HDLs) • Hyperglycemia and diabetes mellitus • Metabolic risk factors • Suicide and suicidality
Important potential risks	• Cerebrovascular adverse events in the elderly • Cerebrovascular adverse events in non-elderly patients • Torsades de Pointes • Ischemic heart disease • Abuse and misuse • Potential for off-label use and misdosing
Missing information	• Use in pregnant or breast-feeding women • Use in patients on concomitant cardiovascular medications • Use in patients on concomitant valproic acid

II.B Summary of important risks

Extrapyramidal symptoms	
Risk minimisation measures	Routine risk minimisation measures: Included in SPC section(s) • 4.4 Special warnings and precautions for use • 4.5 Interaction with other medicinal products and other forms of interaction • 4.6 Fertility, pregnancy and lactation

Extrapyramidal symptoms	
	• 4.8 Undesirable effects • 5.1 Pharmacodynamic properties Included in PL section(s): • 2. What you need to know before you take [Product name] • 4. Possible side effects Additional risk minimisation measures: • Educational material for HCP

Somnolence	
Risk minimisation measures	Routine risk minimisation measures: Included in SPC section(s) • 4.4 Special warnings and precautions for use • 4.5 Interaction with other medicinal products and other forms of interaction • 4.6 Fertility, pregnancy and lactation • 4.8 Undesirable effects • 5.1 Pharmacodynamic properties Included in PL section(s): • 2. What you need to know before you take [Product name] • 3. How to take [Product name] • 4. Possible side effects Additional risk minimisation measures: Prescriber guide Additional risk minimisation measures: • Educational material for HCP

Weight gain	
Risk minimisation measures	Routine risk minimisation measures: Included in SPC section(s)

Weight gain	
	• 4.4 Special warnings and precautions for use • 4.5 Interaction with other medicinal products and other forms of interaction • 4.8 Undesirable effects • 5.1 Pharmacodynamic properties Included in PL section(s): • 2. What you need to know before you take [Product name] • 4. Possible side effects Additional risk minimisation measures: • Educational material for HCP

Lipid changes (increased cholesterol [including increased LDLs], increased triglycerides, and decreased HDLs)	
Risk minimisation measures	Routine risk minimisation measures: Included in SPC section(s) • 4.4 Special warnings and precautions for use • 4.8 Undesirable effects Included in PL section(s): • 4. Possible side effects Additional risk minimisation measures: Educational material for HCP

Hyperglycemia and diabetes mellitus	
Risk minimisation measures	Routine risk minimisation measures: Included in SPC section(s) • 4.4 Special warnings and precautions for use • 4.8 Undesirable effects Included in PL section(s):

Hyperglycemia and diabetes mellitus	
	• 2. What you need to know before you take [Product name] • 4. Possible side effects Additional risk minimisation measures: • Educational material for HCP

Metabolic risk factors	
Risk minimisation measures	Routine risk minimisation measures: Included in SPC section(s) • 4.4 Special warnings and precautions for use • 4.8 Undesirable effects Included in PL section(s): • 4. Possible side effects Additional risk minimisation measures: • Educational material for HCP

Suicide and suicidality	
Risk minimisation measures	Routine risk minimisation measures: Included in SPC section(s) • 4.4 Special warnings and precautions for use • 4.8 Undesirable effects Included in PL section(s): • 2. What you need to know before you take [Product name] • 4. Possible side effects Additional risk minimisation measures: • None

Cerebrovascular adverse events in the elderly	
Risk minimisation measures	Routine risk minimisation measures: Included in SPC section(s) • 4.4 Special warnings and precautions for use • 4.8 Undesirable effects Included in PL section(s): • 2. What you need to know before you take [Product name] • 4. Possible side effects Additional risk minimisation measures: • None

Cerebrovascular adverse events in non-elderly patients	
Risk minimisation measures	Routine risk minimisation measures: Included in SPC section(s) • 4.4 Special warnings and precautions for use • 4.8 Undesirable effects Included in PL section(s): • 4. Possible side effects Additional risk minimisation measures: • None

Torsades de Pointes	
Risk minimisation measures	Routine risk minimisation measures: Included in SPC section(s) • 4.8 Undesirable effects Included in PL section(s): • Not listed Additional risk minimisation measures: • None

Ischemic heart disease	
Risk minimisation measures	Routine risk minimisation measures: Included in SPC section(s) • The relatedness of ischemic heart disease to quetiapine administration has not been confirmed yet Included in PL section(s): • Not listed Additional risk minimisation measures: • None

Abuse and misuse	
Risk minimisation measures	Routine risk minimisation measures: Included in SPC section(s) • 4.4 Special warnings and precautions for use Included in PL section(s): • 2. What you need to know before you take [Product name] Additional risk minimisation measures: • None

Potential for off-label use and misdosing	
Risk minimisation measures	Routine risk minimisation measures: Included in SPC section(s) • 4.1 Therapeutic indications • 4.2 Posology and method of administration Included in PL section(s): • 3. How to take [Product name] Routine risk minimization activities recommending specific clinical measures to address the risk: • None. Additional risk minimisation measures:

Potential for off-label use and misdosing	
	• Educational material for HCP

Use in pregnant or breast-feeding women	
Risk minimisation measures	Routine risk minimisation measures: Included in SPC section(s) • 4.6 Fertility, pregnancy and lactation • 4.8 Undesirable effects Included in PL section(s): • 2. What you need to know before you take [Product name] • 4. Possible side effects Routine risk minimization activities recommending specific clinical measures to address the risk: • None. Additional risk minimisation measures: • None

Use in patients on concomitant cardiovascular medications	
Risk minimisation measures	Routine risk minimisation measures: Included in SPC section(s) • 4.5 Interaction with other medicinal products and other forms of interaction Included in PL section(s): • 2. What you need to know before you take [Product name] Routine risk minimization activities recommending specific clinical measures to address the risk: • None. Additional risk minimisation measures: • None

Use in patients on concomitant valproic acid	
Risk minimisation measures	Routine risk minimisation measures: Included in SPC section(s) • 4.5 Interaction with other medicinal products and other forms of interaction Included in PL section(s): • 2. What you need to know before you take [Product name] Routine risk minimization activities recommending specific clinical measures to address the risk: • None. Additional risk minimisation measures: • None

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Biquetan.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Biquetan.